First Malaria Drug Approved for Newborns and Infants: Novartis Celebrates Breakthrough in Global Health
Basel, July 8, 2025 – In a historic step for global healthcare, the Swiss Agency for Therapeutic Products Swissmedic has granted pharmaceutical company Novartis approval for Coartem Baby (known in some countries as Riamet Baby) – the first malaria drug specifically developed for newborns and infants weighing between 2 and under 5 kilograms. This groundbreaking development closes a long-standing supply gap for the youngest and most vulnerable patients in malaria-endemic regions, particularly in Sub-Saharan Africa, where the disease claims hundreds of thousands of lives annually. Eight African countries involved in the evaluation are close to granting approval as well, which could make the drug available in affected regions in the coming weeks. The new formulation of Coartem Baby, a combination of artemether and lumefantrine, was developed in collaboration with the non-profit organization Medicines for Malaria Venture (MMV). To date, there have been…
